These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 20534739

  • 1. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
    Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, Pandiella A, Terol MJ, García-Marco JA, García-Pardo A.
    Clin Cancer Res; 2010 Sep 01; 16(17):4382-91. PubMed ID: 20534739
    [Abstract] [Full Text] [Related]

  • 2. Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
    Goussetis DJ, Platanias LC.
    Clin Cancer Res; 2010 Sep 01; 16(17):4311-2. PubMed ID: 20622048
    [Abstract] [Full Text] [Related]

  • 3. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.
    Oncotarget; 2015 Dec 29; 6(42):44832-48. PubMed ID: 26540567
    [Abstract] [Full Text] [Related]

  • 4. Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9.
    Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, García-Marco JA, García-Pardo A.
    Oncotarget; 2016 Dec 13; 7(50):83359-83377. PubMed ID: 27829220
    [Abstract] [Full Text] [Related]

  • 5. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
    Calviño E, Estañ MC, Simón GP, Sancho P, Boyano-Adánez Mdel C, de Blas E, Bréard J, Aller P.
    Biochem Pharmacol; 2011 Dec 01; 82(11):1619-29. PubMed ID: 21889928
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
    Lozano-Santos C, Amigo-Jiménez I, Nova-Gurumeta S, Pérez-Sanz N, García-Pardo A, García-Marco JA.
    Biochem Biophys Res Commun; 2015 May 29; 461(2):243-8. PubMed ID: 25869069
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
    Liu ZM, Tseng HY, Cheng YL, Yeh BW, Wu WJ, Huang HS.
    Toxicol Appl Pharmacol; 2015 May 15; 285(1):41-50. PubMed ID: 25791921
    [Abstract] [Full Text] [Related]

  • 11. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
    Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, Hu X, Hou K, Liu Y.
    Cancer Lett; 2009 Nov 01; 284(2):208-15. PubMed ID: 19457607
    [Abstract] [Full Text] [Related]

  • 12. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
    Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T.
    Cancer Sci; 2006 Jun 01; 97(6):540-5. PubMed ID: 16734734
    [Abstract] [Full Text] [Related]

  • 13. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
    Tabellini G, Cappellini A, Tazzari PL, Falà F, Billi AM, Manzoli L, Cocco L, Martelli AM.
    J Cell Physiol; 2005 Feb 01; 202(2):623-34. PubMed ID: 15316930
    [Abstract] [Full Text] [Related]

  • 14. Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways.
    Ho SY, Wu WJ, Chiu HW, Chen YA, Ho YS, Guo HR, Wang YJ.
    Chem Biol Interact; 2011 Sep 05; 193(2):162-71. PubMed ID: 21741957
    [Abstract] [Full Text] [Related]

  • 15. Arsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activation.
    Wu Y, Dai J, Zhang W, Yan R, Zhang Y, Ruan C, Dai K.
    PLoS One; 2014 Sep 05; 9(1):e86445. PubMed ID: 24466103
    [Abstract] [Full Text] [Related]

  • 16. Characterization of arsenic trioxide resistant clones derived from Jurkat leukemia T cell line: focus on PI3K/Akt signaling pathway.
    Roszak J, Smok-Pieniążek A, Nocuń M, Stępnik M.
    Chem Biol Interact; 2013 Oct 05; 205(3):198-211. PubMed ID: 23911876
    [Abstract] [Full Text] [Related]

  • 17. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C, López-Giral S, Alfonso-Pérez M, de Soria VG, Loscertales J, Guasch-Vidal S, Beltrán AE, Zapata JM, Muñoz-Calleja C.
    Exp Hematol; 2010 Sep 05; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [Abstract] [Full Text] [Related]

  • 18. Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation.
    Gwak HS, Park MJ, Park IC, Woo SH, Jin HO, Rhee CH, Jung HW.
    J Neurosurg; 2014 Dec 05; 121(6):1483-91. PubMed ID: 25303017
    [Abstract] [Full Text] [Related]

  • 19. Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
    Amigo-Jiménez I, Bailón E, Ugarte-Berzal E, Aguilera-Montilla N, García-Marco JA, García-Pardo A.
    PLoS One; 2014 Dec 05; 9(6):e99993. PubMed ID: 24956101
    [Abstract] [Full Text] [Related]

  • 20. Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2.
    Binet F, Girard D.
    J Leukoc Biol; 2008 Dec 05; 84(6):1613-22. PubMed ID: 18728151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.